Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171647 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
A Phase 3 study of Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT05171647 is a Phase 3 study of Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 208 participants, above the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT05171647, a Phase 3 study of Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Rituximab
- DRUG Gemcitabine
- DRUG Polatuzumab vedotin
- DRUG Tocilizumab
Study Locations (20)
Other
- Hospital Aleman - Buenos Aires
- Instituto Alexander Fleming - Buenos Aires
- FUNDALEU - Buenos Aires
- Hospital Italiano de Buenos Aires - Ciudad Autonoma Buenos Aires
- D'or Instituto de Pesquisa e Educação - São Paulo
- Sichuan Cancer Hospital - Chengdu
- Fujian Medical University Union Hospital - Fuzhou
- Cancer Center, Sun Yat-sen University of Medical Sciences - Guangzhou
- Tianjin Cancer Hospital - Tianjin
Texas
- Ascension Seton Infusion Center - Austin
- MD Anderson Cancer Center - Houston
São Paulo
- Hospital das Clínicas FMRP-USP - Ribeirão Preto
- Hospital Sao Jose - São Paulo
Ontario
- Hamilton Health Sciences - Juravinski Cancer Centre - Hamilton
- Princess Margaret Hospital - Toronto
California
- City of Hope Cancer Center - Duarte
Missouri
- St. Luke's Hospital - Chesterfield
Paraná
- Hospital Erasto Gaertner - Curitiba
Rio Grande do Sul
- Hospital das Clinicas - UFRGS - Porto Alegre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2022-04-25 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05171647
The ClinicalTrials.gov registry entry for NCT05171647 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (39% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Mosunetuzumab is the first listed.
NCT05171647 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Texas, São Paulo.
Frequently Asked Questions
What is clinical trial NCT05171647 about?
NCT05171647 is a clinical study titled "A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma". This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparis...
What is the current status of trial NCT05171647?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2022-04-25. Estimated completion is 2027-02-28.
What conditions does trial NCT05171647 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05171647?
The interventions under investigation include: Mosunetuzumab (DRUG), Rituximab (DRUG), Gemcitabine (DRUG), Polatuzumab vedotin (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT05171647?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05171647 being conducted?
This trial has 20 study locations across California, Missouri, Texas, Paraná, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RECRUITING · Phase 3
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
-
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.